Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes

Postgraduate Medicine

Volumn 126, Issue 6, 2014, Pages 60-71

  Kuritzky, Louis ^a   Umpierrez, Guillermo ^b   Ekoé, Jean Marie ^c   Mancillas Adame, Leonardo ^d   Landó, Laura Fernández ^d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Dulaglutide; GLP 1 receptor agonist; Primary care; Type 2 diabetes

Indexed keywords

DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; PEPTIDE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; VENOM;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; HYPOTENSION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); THYROID HYPERPLASIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG COMBINATION;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; METFORMIN; PEPTIDES; PYRAZINES; RECEPTORS, GLUCAGON; RECOMBINANT FUSION PROTEINS; THIAZOLIDINEDIONES; TRIAZOLES; VENOMS;

EID: 84922392829     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.10.2821     Document Type: Article

References (79)

1. Schwartz SS. A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Curr Med Res Opin. 2013;29(7):793–799.
2. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203.
3. Ahren B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes Metab. 2013;39(3):195–201.
4. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(suppl 2):S127–S138.
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.
6. US Department of Health and Human Services CDC. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States. Washington, DC; 2011.
7. Public Health Agency of Canada. Diabetes in Canada: Facts and figures from a public health perspective. Ottowa, Ontario; 2011.
8. Siminerio LM, Drab SR, Gabbay RA, et al. Diabetes educators: implementing the chronic care model. Diabetes Educ. 2008;34(3): 451–456.
9. Ryden L, Standl E, Bartnik M, et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136.
10. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.
11. Harper W, Clement M, Goldenberg R, et al; Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic Management of Type 2 Diabetes; Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Can J Diabetes. 2013;37(suppl 1):S61–S68.
12. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082.
13. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705.
14. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagonlike peptide-1 7–36: a physiological incretin in man. Lancet. 1987;2(8571):1300–1304.
15. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia. 1995;38(6):720–725.
16. Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr. 1998;68(3): 525–530.
17. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38(4):665–673.
18. Näslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Dis. 1999;23(3):304–311.
19. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–744.
20. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126–1131.
21. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36(11–12):761–765.
22. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2007;14(2):98–107.
23. Pena A, Loghin C, Cui X, et al. Pharmacokinetics of once weekly dulaglutide in patients with type 2 diabetes mellitus. Presented at: American Diabetes Association. San Francisco, CA; 2014.
24. Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26(4):287–296.
25. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care. 2014;37(8):2149–2158.
26. Ahren B, Johnson SL, Stewart M, et al. HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin. Diabetes Care. 2014;37(8):2141–2148.
27. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, openlabel trial. Lancet. 2010;375(9724):1447–1456.
28. Russell-Jones D, Cuddihy RM, Hanefeld M, et al; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–258.
29. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012;34(6):1247–1258. e22.
30. Ahren B, Stewart M, Cirkel D, Yang F, Perry C, Johnson S. HARMONY 3: 104 Week (Wk) Efficacy of Albiglutide (Albi) Compared to Sitagliptin (Sita) and Glimepiride (SU) in Patients (pts) with Type 2 Diabetes Mellitus (T2DM) on Metformin (Met). Presented at: American Diabetes Association 73rd Annual Meeting. Chicago, IL; 2013.
31. Rodbard HW. Increased priority for regimens involving incretinbased and insulin therapy. J Fam Pract. 2013;62(12 suppl CME): S5–S11.
32. Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(5):426–433.
33. Loghin C, Pena A, Xuewei C, Zhang X, Geiser J, Chien J. Pharmacokinetics of Once Weekly Dulaglutide in Special Populations. Presented at: American Diabetes Associatoin 74th Annual Meeting. San Francisco, CA; 2014.
34. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–2668.
35. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29(10): 1260–1267.
36. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Met. 2011;13(5):418–425.
37. Wysham C, Blevins T, Arakaki R, et al. Efficacy and Safety of Dulaglutide Added on to Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care. 2014;37(8):2159–2167.
38. Umpierrez G, Povedano ST, Manghi FP, Shurzinske L, Pechtner V. Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3). Diabetes Care. 2014;37(8):2168–2176.
39. Skrivanek Z, Gaydos BL, Chien JY, et al. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab. 2014;16(8):748–756.
40. Weinstock R, Umpierrez G, Guerci B, et al. Safety and Efficacy of Dulaglutide vs Sitagliptin after 104 Weeks in Type 2 Diabetes (AWARD- 5). Presented at: American Diabetes Association 73rd Annual Meeting. Chicago, IL; 2013.
41. Ferdinand K, Calhoun D, Lonn E, et al. Effects of Dulaglutide, a GLP-1 agonist, on Ambulatory Diurnal and Nocturnal Blood Pressure in Patients with Type 2 Diabetes (abstract). Presented at: American Society of Hypertension 2013 Conference. San Francisco, CA; 2013.
42. Matfin G, Zimmermann A, Van Brunt K, Threlkeld R, Ignaut D. Safe and effective use of the single-use pen for injection of once weekly dulaglutide in injection-naïve patients with type 2 diabetes. American Diabetes Association. 2014;74th Annual Scientific Sessions. 2014;63(suppl 1A): LB31.
43. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33(2): 428–433.
44. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019–1027.
45. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med. 2008;358(18):1970–1971.
46. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–156.
47. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care. 2013;36(7):2118–2125.
48. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534–539.
49. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11): 2349–2354.
50. Xu G, Kaneto H, Lopez-Avalos MD, Weir GC, Bonner-Weir S. GLP-1/ exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract. 2006;73(1):107–110.
51. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61(5):1250–1262.
52. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32(5):834–838.
53. Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab. 2010;12(9):766–771.
54. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–1486.
55. Novo Nordisk’s Liraglutide (injection) for the treatment of patients with type 2 diabetes, NDA 22–341, briefing document: Endocrine and Metabolic Drug Advisory Committee 2 April 2009. In: Administration FFaD, ed. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic- DrugsAdvisoryCommittee/UCM148659.pdf2009. Accessed August 28, 2014.
56. Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer. Oncologist. 2013;18(10):1093–1100.
57. Moraitis AG, Martucci VL, Pacak K. Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma/ paraganglioma. Endocr Pract. 2014;20(2):176–187.
58. Home P, Stewart M, Yang F, Perry C, Carr M. 52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes: HARMONY5 Study. Presented at: American Diabetes Association 73rd Annual Meeting. Chicago, IL; 2013.
59. Tanzeum [package insert]. Research Triangle Park, NC: GlaxoSmith- Kline; 2014.
60. Byetta [package insert]. San Diego, CA: AstraZeneca; 2005.
61. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477–485.
62. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091.
63. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide- 113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635.
64. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100.
65. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333–2348.
66. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559–569.
67. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259–267.
68. Bydureon [package insert]. San Diego, CA: AstraZeneca; 2012.
69. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–124.
70. Buse JB, Drucker DJ, Taylor KL, et al; DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33(6):1255–1261.
71. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234–2243.
72. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310.
73. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.
74. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 MetTZD). Diabetes Care. 2009;32(7):1224–1230.
75. Marre M, Shaw J, Brandle M, et al; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–278.
76. Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.
77. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1). Presented at: EASD 49th Annual Meeting. Barcelona, Spain; 2013.
78. Victoza [package insert]. Princeton, NJ: NovoNordisk; 2010.
79. Lyxumia [package insert]. Paris, France: Sanofi; 2013.